Oncology

Payment reform may be used to better align appropriate financial incentives with better quality of care.

The development of subspecialty tumor groups for uncommon malignancies represents an effective approach to building experience, increasing patient volumes and referrals, and fostering development of increased therapeutic options and clinical trials for patients afflicted with otherwise historically neglected cancers.

There have been many research advancements in oncology over the past several weeks, including a new blood test designed to predict the onset of breast cancer; new control techniques for oncology payer management; and the creation of a new electronic tool for oncology nurses to improve patient outcomes.

The American Journal of Managed Care team had the opportunity to attend the Academy of Managed Care Pharmacy's 24th Annual Meeting in San Francisco this past week. Here are some of the key takeaways from the very informative sessions.

In this video, Mark Zitter, MBA, CEO of the Zitter Group, speaks about how oncology pathways are affecting drug use.

Wednesday morning at the Academy of Managed Care Pharmacy 24th Annual Meeting featured a satellite symposium that focused on the evolving role of managed care and oncology pharmacy management. The presentations by distinguished faculty reviewed current evidence-based data to enable decision making based on indicators of treatment outcomes for multiple myeloma; demonstrated the use of comparative effectiveness research (CER) as a decision support tool; and evaluated innovative pharmacy benefit models and specialty management services.

Metabolomics, Proteomics, and Epigenetics

Why Oncologists Must Tailor Clinical Features to Their Needs

Promise and Pitfalls Along the Path to Personalized Care

The Duke Cancer Institute

To help oncology providers better understand drug mechanisms of action, and the economic implications of their use.

Review of the most recent evidence-based literature discussing breast, colorectal, lung, and ovarian cancers, in addition to melanoma and multiple myeloma.

How Much Do We Spend and How Can We Spend It Better?

Insights Into Value-Based Insurance Design in Oncology

Radical Changes in Payment Incentives and Elimination of Low-Value Care

Health Plans Continue to Seek Methods to Curtail Cancer Costs

Grim Reality Is a Bitter Pill to Swallow: Interview with Michael P. Link, MD, ASCO President

The Challenges Facing Oncologists Are Formidable